CN114939162B - Multifunctional nano catalyst for ultrasonic-mediated bio-orthogonal reaction and preparation method and application thereof - Google Patents
Multifunctional nano catalyst for ultrasonic-mediated bio-orthogonal reaction and preparation method and application thereof Download PDFInfo
- Publication number
- CN114939162B CN114939162B CN202210294854.XA CN202210294854A CN114939162B CN 114939162 B CN114939162 B CN 114939162B CN 202210294854 A CN202210294854 A CN 202210294854A CN 114939162 B CN114939162 B CN 114939162B
- Authority
- CN
- China
- Prior art keywords
- reaction
- ultrasonic
- solution
- multifunctional
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 66
- 239000011943 nanocatalyst Substances 0.000 title claims abstract description 49
- 230000001404 mediated effect Effects 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 40
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 18
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 238000011065 in-situ storage Methods 0.000 claims abstract description 5
- 229920000642 polymer Polymers 0.000 claims abstract description 5
- 239000002872 contrast media Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 238000002604 ultrasonography Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 239000002243 precursor Substances 0.000 claims description 13
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 11
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 230000006698 induction Effects 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- -1 polytetrafluoroethylene Polymers 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- DEIGKMHFWPVXRW-UHFFFAOYSA-N 5-azido-1,2,3-trimethoxybenzene Chemical group COC1=CC(N=[N+]=[N-])=CC(OC)=C1OC DEIGKMHFWPVXRW-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- KKJNQKVCZCNJDI-UHFFFAOYSA-N 3-azido-7-hydroxychromen-2-one Chemical compound C1=C(N=[N+]=[N-])C(=O)OC2=CC(O)=CC=C21 KKJNQKVCZCNJDI-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 37
- 238000003384 imaging method Methods 0.000 abstract description 17
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 6
- 239000001301 oxygen Substances 0.000 abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 abstract description 6
- 230000003197 catalytic effect Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000002595 magnetic resonance imaging Methods 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 238000001027 hydrothermal synthesis Methods 0.000 abstract description 2
- 239000010949 copper Substances 0.000 description 19
- 239000003054 catalyst Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000010461 azide-alkyne cycloaddition reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000007036 catalytic synthesis reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002082 metal nanoparticle Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007809 chemical reaction catalyst Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/225—Microparticles, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/06—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing polymers
- B01J31/069—Hybrid organic-inorganic polymers, e.g. silica derivatized with organic groups
Abstract
The invention discloses a multifunctional nano catalyst for ultrasonic-mediated bio-orthogonal reaction and a preparation method and application thereof. The multifunctional nano catalyst of the invention is prepared by Cu-containing 2+ The compound and the macromolecular polymer are obtained by a hydrothermal synthesis method, and the compound and the macromolecular polymer are subjected to ultrasonic-induced catalytic bio-orthogonal reaction. The multifunctional nano catalyst can be used as a sound sensitive agent to generate a large amount of active oxygen under the ultrasonic action while selectively controlling the in-vivo in-situ drug synthesis in an ultrasonic manner, and can also be used as a contrast agent for Magnetic Resonance Imaging (MRI) and photoacoustic imaging (PAI), so that the visualized biological orthogonal and acoustic dynamic (SDT) synergistic anti-tumor effect is realized.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to a subminiature multifunctional nano catalyst for ultrasonic-mediated biological orthogonal reaction, a preparation method and biological application thereof.
Background
Cancer has been one of the most fatal diseases among various diseases in the world, and seriously threatens the life and health of human beings. Chemotherapy is widely used clinically as a cornerstone of a variety of anti-cancer strategies. However, chemotherapy is prone to cause some toxic and side effects (fatigue, nausea, vomiting, hair loss, weight loss, bleeding, susceptibility to infection, etc.) due to its non-specific targeting, poor bioavailability, rapid inactivation, drug resistance, poor pharmacokinetics, etc. In order to solve these problems, the development of a reliable therapeutic regimen and a feasible drug synthesis strategy with promising clinical application prospects is urgently needed.
The bio-orthogonal reaction is a biological process that is carried out in vivo in a living organism and is not interfered by other spontaneous reactions in the organism. Bio-orthogonality is currently widely used in the field of nanomedicine due to its possessing some bio-functional applications. For example: marking biomolecules such as proteins and nucleic acids, selectively activating inactive substances in biological environments, cell surface functionalization, in vivo imaging monitoring and the like. These bioorthogonal reactions are satisfactorily achieved in living systems.
In recent years, bioorthogonal transformations mediated by biocompatible metal catalysts have shown great potential for applications in synthetic biology and medicinal chemistry, which can promote or accelerate reactions and, in addition, can achieve new chemical reactions in organisms that cannot be catalyzed by natural enzymes. Currently, the most widely used metal catalysts for such conversion applications are mainly Cu, pd, ru, ir, fe and Au. These catalysts promote the bioorthogonal reactions to proceed smoothly, mainly by participating in bond cleavage, cross-coupling, and cycloaddition reactions. However, the reported metal catalysts have limited their application in complex organisms due to their potential biological toxicity, poor water solubility, low dispersibility, difficult metabolism and poor stability.
With the continuous development of the bioorthogonal reaction in the field of nano medicine, the controllable regulation and the on-demand catalysis of the bioorthogonal reaction in organisms and the like are further explored. For example, the literature reports the use of visible, ultraviolet and near-infrared light as external stimuli for controlling the occurrence of bioorthogonal reactions, but the unavoidably limited penetration of the light source limits its further use in the body.
Disclosure of Invention
In order to solve the problems, the invention designs and synthesizes a subminiature multifunctional nano-catalyst for ultrasonic-mediated bio-orthogonal reaction, which overcomes the defects of potential biological toxicity, poor water solubility, low dispersibility, difficult metabolism, poor stability and the like of the traditional metal catalyst and also endows the catalyst with some new functions, such as: the nano-catalyst can realize MR and PA imaging while selectively ultrasonically controlling in-vivo in-situ drug synthesis, and can also be used as a sonosensitizer to generate a large amount of Reactive Oxygen Species (ROS), so that visual biological orthogonal interaction and Sonodynamic (SDT) synergistic antitumor effect is realized.
In a first aspect, the present invention provides a subminiature multifunctional nanocatalyst for ultrasound-mediated bio-orthogonal reaction, which catalyzes the bio-orthogonal reaction by ultrasound induction, the multifunctional nanocatalyst is prepared from Cu-containing catalyst 2+ The compound (2) and the macromolecular polymer are obtained by a hydrothermal synthesis method; the macromolecular polymer is sodium polyacrylate.
The multifunctional nano catalyst is characterized in that metal nano particles of the multifunctional nano catalyst are obtained by modifying sodium polyacrylate, so that the metal nano particles can exist stably in organisms, and in a preferable scheme, the average molecular weight Mw of the sodium polyacrylate is 1200.
The multifunctional nano catalyst (Cu @ P NCs for short) can realize the generation of ultrasonic mediated biological orthogonal reaction, has the effect of triggering SDT treatment, and has MR and PA imaging capabilities.
In a second aspect, the invention provides a preparation method of the multifunctional nano catalyst Cu @ P NCs, which comprises the following steps:
(1) Solution preparation:
preparation of Cu (NO) at a concentration of 0.3M 3 ) 2 ·3H 2 Aqueous solution of O: 0.7248g of Cu (NO) is weighed 3 ) 2 ·3H 2 Dissolving O in 10mL of deionized water, and performing ultrasonic dispersion to dissolve the O;
preparation of Na at a concentration of 0.3M 2 HPO 4 ·12H 2 O aqueous solution: 1.0744g of Na was weighed 2 HPO 4 ·12H 2 O dissolved in 10mL to removeUltrasonically dispersing and dissolving in water;
preparation of a 1M aqueous NaOH solution: 0.4g of NaOH was weighed out and dissolved in 10mL of deionized water, and the solution was dispersed by sonication and allowed to dissolve.
(2) The synthesis steps are as follows:
adding Cu (NO) 3 ) 2 ·3H 2 O (4 mL) aqueous solution and sodium polyacrylate (0.36 g) were dissolved in deionized water (40 mL), and the mixture was stirred to obtain a uniform mixture, followed by adding Na to the mixture 2 HPO 4 ·12H 2 Continuously stirring an O (2 mL) solution, then adjusting the pH value to 7.0 by using a NaOH solution, and finally transferring the reaction solution to a 100mL polytetrafluoroethylene reaction kettle, lining the reaction kettle, and heating for 6 hours at 120 ℃; after cooling to room temperature, extraction with cyclohexane followed by centrifugation with ethanol precipitation gave a blue product, which was washed several times with water and ethanol to remove unreacted reagents. Finally obtaining the ultra-small multifunctional nano catalyst Cu @ P NCs.
In particular, cu (NO) 3 )2·3H 2 The mass ratio of O to sodium polyacrylate is 1: 1.25; in the process of precipitating the reaction solution by using ethanol, absolute ethanol is needed, and the volume of the absolute ethanol is more than 10 times of that of the reaction solution; the precipitate was washed with water and ethanol in a volume ratio of (3: 7).
In a third aspect, according to the application of the multifunctional nano-catalyst in tumor therapy, the multifunctional nano-catalyst catalyzes bio-orthogonal reaction through ultrasonic induction during tumor therapy, and is used as a sound sensitive agent to realize SDT, and is also used as a contrast agent material for MRI and PAI.
In a fourth aspect, the present invention provides a composition for tumor therapy by bioorthogonal reaction, comprising a precursor and the multifunctional nanocatalyst as described above, wherein the multifunctional nanocatalyst catalyzes the precursor to bioorthogonal reaction by ultrasonic induction.
In a preferable scheme, the composition is used for ultrasonic-mediated fluorescent molecule synthesis, the precursors are fluorescent precursor combinations (drug 1 and drug 2), the multifunctional nano catalyst can trigger the synthesis of a fluorescent reporter molecule by ultrasonic, the occurrence of bioorthogonal reaction in cells is shown in real time through a fluorescent reporting strategy, and the synthetic route of the drug 1 and the drug 2 is as follows.
A
B
anhydrous NaOAc: anhydrous sodium acetate; ac of 2 O: acetic acid; HCl: hydrochloric acid; ethanal: ethanol; naNO 2 : sodium nitrate; naN 3 : sodium azide; DMF: n-dimethylformamide; HBTU is O-benzotriazole-tetramethyluronium hexafluorophosphate; DIPEA: diisopropylethylamine.
In another preferred scheme, the composition is used for in-situ synthesis of active drugs, the precursor is a drug precursor combination (drug 4 and drug 5), the ultra-small multifunctional nano catalyst can trigger in-situ synthesis of the active drugs by ultrasound, and the synthesis routes of the drug 4 and the drug 5 are as follows.
C
D
NaN 3 : sodium azide; HCl: hydrochloric acid; pd (PPh 3) 4: palladium tetrakistriphenylphosphine; and (2) CuI: copper iodide; THF: tetrahydrofuran; et3N: triethylamine; TABF: tetrabutylammonium fluoride.
In the composition for treating tumor, the multifunctional nano-catalyst can be used as a sound-sensitive agent to induce the generation of ROS, so that the combined treatment of bio-orthogonal reaction and SDT is realized, and the effect of inhibiting the activity of tumor is excellent.
In the composition for tumor treatment, the multifunctional nano catalyst also has MR and PA imaging capabilities, and realizes the purpose of diagnosis and treatment integration.
The invention has the following beneficial effects:
the invention successfully designs and synthesizes the microminiature multifunctional high-efficiency catalyst Cu @ P NCs by utilizing the sodium polyacrylate modified copper nano particles. Under the condition of hypoxia in tumors, the catalyst can trigger the generation of Cu (I) active sites in Cu @ P NCs through ultrasound, further realize Cu (I) -mediated azide-alkyne cycloaddition reaction, generate active drugs at tumor parts, avoid the problems of toxic and side effects on normal cells and the like caused by low targeting of traditional therapeutic drugs, and effectively kill tumor cells. On the other hand, the generation of the time-space control bio-orthogonal reaction can be realized through ultrasound, and the problem that the traditional bio-orthogonal reaction catalyst is lack of selective on-demand synthesis of active drugs is solved. Meanwhile, separation of electrons and holes in the Cu @ P NCs is caused in the ultrasonic process, the Cu @ P NCs is endowed with the function of a sound-sensitive agent, a large amount of ROS can be generated, oxygen can be consumed, the biological orthogonal reaction can be positively promoted, and the SDT treatment is cooperated, so that the effect of efficiently amplifying the anti-tumor effect is realized. In addition, due to the special properties of Cu @ P NCs, the aim of diagnosis and treatment integration is achieved through MR and PA imaging. More importantly, compared with other metal catalysts, the Cu @ P NCs have the advantages of good water solubility, high bioavailability, capability of being discharged out of the body through renal metabolism, no toxic or side effect on the body and the like.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required to be used in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and those skilled in the art can also obtain other related drawings based on the drawings without inventive efforts.
FIG. 1 is a Transmission Electron Microscope (TEM) photograph of the multifunctional nano-catalyst Cu @ P NCs prepared in example 1 of the present invention;
FIG. 2 shows that the multifunctional nano-catalyst Cu @ P NCs in example 2 generates Cu (I) active sites under ultrasonic induction;
FIG. 3 shows the ultrasonic mediated bio-orthogonal catalytic synthesis of fluorescent reporter group by the multifunctional nano-catalyst Cu @ P NCs in example 3;
FIG. 4 shows the ultrasonic mediated bio-orthogonal catalytic synthesis of active drug molecules by the multifunctional nano-catalyst Cu @ P NCs in example 4;
FIG. 5 shows that multifunctional nano-catalyst Cu @ P NCs as sonosensitizers can generate large amounts of ROS;
figure 6 shows the results of in vitro treatment evaluation of ultrasound-mediated bio-orthogonal synergistic SDT in example 6;
FIG. 7 shows the test results of multi-functional nano-catalyst Cu @ P NCs multi-modal imaging in example 7.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The copper nano-composite is modified by utilizing sodium polyacrylate, an ultra-small multifunctional nano-catalyst Cu @ P NCs is synthesized, and the controllable performance of efficiently catalyzing biological orthogonal reaction is realized by ultrasonic triggering. Under the stimulation of exogenous ultrasonic waves, the catalytic activity of Cu @ P NCs can be regulated and controlled through reversible valence conversion between Cu (II) and Cu (I). After the Cu @ P NCs are internalized into cells, the Cu @ P NCs are ultrasonically triggered to generate Cu (I) active sites, and then the azide-alkyne cycloaddition reaction is catalyzed through typical Cu (I) to locally catalyze the drug synthesis. Meanwhile, electrons and holes in the Cu @ P NCs are separated in the process of ultrasonic catalysis, so that the Cu @ P NCs are endowed with the function of the sound-sensitive agent, and the ultrasonic triggering of the generation of active oxygen enables the sound-sensitive agent to generate a large amount of active oxygen and consume oxygen, thereby greatly promoting the implementation of the hypoxic biological orthogonal reaction and achieving the purpose of efficiently killing tumor cells. Meanwhile, the Cu @ P NCs have strong near infrared absorption and unpaired electron pairs on the Cu outermost layer track, so that the photoacoustic imaging and nuclear magnetic resonance imaging capabilities are endowed, and the visualization of the treatment process is realized.
The present invention will be described in further detail with reference to examples. It is also to be understood that the following examples are illustrative of the present invention and are not to be construed as limiting the scope of the invention, and that insubstantial modifications and adaptations of the invention by those skilled in the art based on the foregoing description are intended to be included within the scope of the invention. The specific process parameters and the like of the following examples are also only one example of suitable ranges, i.e., those skilled in the art can select the appropriate ranges through the description herein, and are not limited to the specific values exemplified below.
EXAMPLE 1 preparation of multifunctional Nanocatalysts Cu @ P NCs 4mL of Cu (NO) 3 ) 2 ·3H 2 An aqueous solution of O (0.3M) and 0.36g of sodium polyacrylate were dissolved in 40mL of deionized water, and the mixture was stirred at room temperature for 15min to obtain a uniform solution. Then, 2mL of Na was added to the mixture 2 HPO 4 ·12H 2 The O solution was stirred at room temperature for 2h and then the pH was adjusted to 7.0 with NaOH solution. And finally, transferring the reaction solution to a 100mL polytetrafluoroethylene reaction kettle, and heating the lining in the high-pressure reaction kettle at 120 ℃ for 6 hours. After cooling to room temperature, centrifugation (13000rpm, 10 min) was carried out using ethanol precipitation to give a blue product, and washing with water and ethanol was carried out several times to remove unreacted reagents. Finally obtaining the ultra-small multifunctional nano catalyst Cu @ P NCs.
FIG. 1 is a TEM image of the multifunctional nanocatalyst of Cu @ PNCs in this example. As can be seen from FIG. 1, cu @ PNCs have a uniform spherical distribution and a particle size of about 3nm.
Example 2
Ultrasonic induction of subminiature multifunctional nano catalyst Cu @ P NCs to generate Cu (I) active sites: selecting a new cuprous reagent as an indicator for detecting the generation of Cu (I) active sites of Cu @ P NCs under ultrasonic induction. Firstly, 1.04mg of cuprous reagent is weighed and dissolved in 5mL of absolute ethyl alcoholThen diluted 5 times with deionized water for use. Then buffer solution with pH of 6.2 is prepared for standby, and KH is used 2 PO 4 And NaOH to adjust pH. Weigh 5mg of Cu @ P NCs into 10mL of deionized water at a concentration of 500. Mu.g/mL for use. The final detection working solution contained 0.75mL buffer, 1.0mL Cu @ P NCs solution and 0.8mL new cuprous reagent, and the working solution was exposed to ultrasound at 1MHz and 1.5W/cm 2 And carrying out ultrasonic treatment for 10min under the condition that the duty ratio is 50%, and finally measuring the absorbance of the working solution at the wavelength of 450nm by using an ultraviolet-visible absorption spectrum. FIG. 2 shows the UV absorption spectrum of Cu @ P NCs generated Cu (I) active sites under ultrasonic excitation in this example. From the spectra we can see that with increasing ultrasound time and ultrasound power, more and more Cu (I) active species are generated.
Example 3
Ultrasonic mediated fluorescence molecule synthesis: firstly, a mixed solution of a metal catalyst Cu @ P NCs (1 mg/mL) and drug molecules of 3-azide-7-hydroxycoumarin (drug 1, 100 mu M) and 6-oxo-6- (propynyl-2-ene-1-oxyammonio) hexyl) triphenylphosphine (drug 2, 100 mu M) is placed in a six-hole plate, and the mixed solution is subjected to ultrasonic treatment for 10min (1 MHz, 1.5W/cm) by using an ultrasonic probe 2 Duty 50%), then the mixture was transferred to a three-necked flask and the reaction was stirred continuously at 37 ℃ under nitrogen. During the reaction, the reaction solutions were collected for 0.5, 1.0, 1.5 and 2.0 hours, respectively, and the fluorescence intensities (E) of the reaction solutions at different time points were monitored by fluorescence spectroscopy x /E m :＝347/482nm)。
FIG. 3 shows the results of ultrasound-mediated synthesis of fluorescent molecules. As can be seen from FIG. 3, the reaction solution emits a strong fluorescence signal after the ultrasonic treatment.
Example 4
Ultrasonic mediated drug molecule synthesis: a pair of safe and nontoxic small molecules are converted into toxic small molecules, so that the antitumor therapy is realized. In the first step, we verified the in vitro synthesis of active drug molecules by high performance liquid chromatography. The specific implementation steps are as follows: first, a metal catalyst Cu @ P NCs (1 mg/mL) was mixed with 5-azido-1, 2, 3-trimethoxybenzene (drug 4, 100. Mu.M) and drug moleculesPlacing 5-acetylene-2-methoxyaniline (drug 5, 100 μ M) mixed solution in six-well plate, and subjecting the mixed solution to ultrasound with ultrasonic probe for 10min (1 MHz, 1.5W/cm) 2 Duty 50%) and then the mixture was transferred to a three-necked flask and the reaction was stirred continuously at 37 ℃ under nitrogen atmosphere. During the reaction, the reaction solutions were collected for 2,4,8 and 24 hours, respectively, and after centrifugation (13000rpm, 10min) for purification, the newly produced compound was monitored by high performance liquid chromatography.
FIG. 4 shows the formation of active drug molecules by HPLC, and from FIG. 4 we can see that new peaks appear, and the yield of the product is higher and higher with longer reaction time, and the content of the reactant is reduced accordingly.
Example 5
And (3) testing the generation of ROS (reactive oxygen species) induced by the microminiature multifunctional nano catalyst Cu @ P NCs as a sonosensitizer.
FIG. 5 shows the monitoring of ROS production using Electron paramagnetic resonance (ESR). As can be seen from figure 5, under the condition of ultrasonic stimulation, cu @ P NCs can obviously generate singlet oxygen (S) ((R)) 1 O 2 ) Superoxide anion (O) - 2 ) And hydroxyl radicals (. OH); however, without sonication, there is little production of singlet oxygen, superoxide anions, and hydroxyl radicals. The Cu @ P NCs are stimulated by ultrasound to cause the separation of electrons and holes in the Cu @ P NCs, so that the Cu @ P NCs can be used as a high-efficiency sound-sensitive agent to absorb the energy released by the ultrasound, further generate a large amount of ROS, consume oxygen, enhance the treatment effect of the SDT and greatly improve the catalytic efficiency under the bioorthogonal hypoxic condition.
Example 6 ultrasound-mediated bio-orthogonal responses in conjunction with testing of SDT for anti-tumor proliferation inhibitory activity in vitro, demonstrated therapeutic levels of synthetic active drug in vitro at the cellular level. First, 4T1 cells were plated at 5X 10 per well 3 The density of (2) was inoculated in a 96-well plate and cultured for 24h before starting the treatment. The mixed culture solution containing drug 4 (20. Mu.M) and drug 5 (20. Mu.M), drug 4 (20. Mu.M), drug 5 (20. Mu.M) and metal catalyst were usedInstead of the complete culture medium, a mixed culture medium of Cu @ P NCs (100. Mu.g/mL) was used. Then, they were sonicated and not sonicated, respectively, and they were co-cultured in an anaerobic culture bag for 12 hours, and the complete medium culture and the non-sonicated group were used as negative control groups. After the end of the incubation, the cells were washed twice with PBS buffer, then 100 μ L of fresh medium containing the cell counting reagent cck-8 (10 μ L) was added per well and incubated with the cells for 1h, and finally, their absorbance at 450nm was recorded by a microplate reader.
FIG. 6 shows the results of the study of the proliferation inhibitory activity of mouse breast cancer cells 4T1 by ultrasound-mediated bio-orthogonal reaction in cooperation with SDT. As can be seen from FIG. 6 (a-b), the cytotoxicity of drug 4, drug 5 and Cu @ P NCs was almost negligible, and the survival rate of cells reached more than 90% even at drug concentrations of 80. Mu.M or 80. Mu.g/mL. However, as can be seen from FIG. 6 (b), the survival rate of 4T1 cells under Ultrasonic (US) stimulation was significantly decreased with the increase in the concentration of Cu @ P NCs, and was 58.1% when the concentration reached 80. Mu.g/mL. In addition, we found that the cell viability of cu @ p NCs was significantly reduced to 36.8% compared to SDT triggered by cu @ p NCs alone after US treatment of cu @ p NCs, drug 4 and drug 5 in the presence of both. The result shows that the SDT combined bioorthogonal reaction triggered by Cu @ P NCs further enhances the killing effect on tumor cells.
Example 7 testing of multi-functional nano-catalyst Cu @ P NCs multimodal imaging capability.
We examined MR and PA imaging of Cu @ P NCs in mice. The 4T1 tumor cells are first inoculated at a density of 1X 10 7 Inoculating to leg or armpit of mouse, and allowing tumor volume to reach 250mm 3 Left and right, tumor-bearing mice were treated for MR and PA imaging. For PA and MR imaging, we injected the nano-catalyst Cu @ P NCs intratumorally into mice, 2h later, mice were scanned and imaged using a clinical MRI scanner (Siemens prism MR 3.0T, germany) and a small animal PA imaging system (VEVO LAZR-X, USA), respectively, and in addition, images of mice before injection of the nano-catalyst served as negative controls.
FIG. 7 shows bimodal imaging results of Cu @ P NCs in tumor-bearing mice. For PA imaging, from fig. 7 (a), the PA signal at the tumor site was significantly enhanced after cu @ p NCs injection, demonstrating its ability to be PA imaged. In addition, as for the MR imaging, as can be seen from fig. 7 (b), the contrast of MR imaging at the tumor site was significantly enhanced compared to other tissues after the injection of cu @ p NCs. The above results indicate that Cu @ P NCs can be used as a novel and promising MR/PA bimodal imaging contrast agent.
The cell and animal experiments of the embodiment verify that the precursor compounds can be selectively activated in tumor cells, so that the bioorthogonal reaction is cooperated with SDT treatment to achieve a high-efficiency anti-tumor effect.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (7)
1. The multifunctional nano catalyst for the ultrasonic-mediated bio-orthogonal reaction is characterized in that the ultrasonic-induced catalysis of the bio-orthogonal reaction is performed, and the multifunctional nano catalyst is prepared from Cu-containing Cu 2+ A complex of the compound of (a) and a macromolecular polymer;
the preparation method of the multifunctional nano catalyst comprises the following steps: adding Cu (NO) 3 ) 2 •3H 2 Dissolving O water solution and sodium polyacrylate in deionized water, stirring to obtain uniform mixed solution, and adding Na into the mixed solution 2 HPO 4 ·12H 2 Continuously stirring O solution, adjusting pH to 7.0 with NaOH solution, transferring the reaction solution to 100mL polytetrafluoroethylene reaction kettle lining, heating at 120 deg.C for 6h, cooling to room temperature, extracting with cyclohexaneTaking, then precipitating and centrifuging by using ethanol to obtain a blue product, washing the blue product by using water and ethanol for several times to remove unreacted reagents, and finally obtaining the multifunctional nano catalyst Cu @ P NCs.
2. A method of preparing the multifunctional nanocatalyst of claim 1, comprising the steps of:
adding Cu (NO) 3 ) 2 •3H 2 Dissolving O water solution and sodium polyacrylate in deionized water, stirring to obtain uniform mixed solution, and adding Na into the mixed solution 2 HPO 4 ·12H 2 And continuously stirring the O solution, then adjusting the pH value to 7.0 by using a NaOH solution, finally transferring the reaction solution to a 100mL polytetrafluoroethylene reaction kettle lining, heating the reaction solution in the high-pressure reaction kettle at 120 ℃ for 6h, cooling the reaction solution to room temperature, then extracting the reaction solution by using cyclohexane, then precipitating and centrifuging the reaction solution by using ethanol to obtain a blue product, washing the blue product by using water and ethanol for several times to remove unreacted reagents, and finally obtaining the multifunctional nano catalyst Cu @ PNCs.
3. The method as set forth in claim 2, wherein Cu (NO) 3 ) 2 •3H 2 The mass ratio of O to sodium polyacrylate is 1: 1.25; when the reaction solution is precipitated by ethanol, the volume of the ethanol is more than 10 times of that of the reaction solution, and when the precipitate is washed by the ethanol and the water, the volume ratio of the ethanol to the water is 7:3.
4. the use of the multifunctional nanocatalyst of claim 1 in the preparation of a medicament for the treatment of tumors, wherein the multifunctional nanocatalyst catalyzes the bioorthogonal reaction through ultrasonic induction during the treatment of tumors and serves as a sonosensitizer to achieve sonodynamic treatment of tumors.
5. Use of the multifunctional nanocatalyst of claim 1 in the preparation of MRI and PAI contrast agent materials.
6. A composition for tumor therapy by bioorthogonal reaction, comprising a precursor and the multifunctional nanocatalyst of claim 1, which catalyzes the precursor to bioorthogonal reaction by ultrasound induction;
the composition is used for ultrasonic-mediated fluorescent molecule synthesis, and the precursors are 3-azido-7-hydroxycoumarin and
。
7. a composition for tumor therapy by bioorthogonal reaction, comprising a precursor and the multifunctional nanocatalyst of claim 1, which catalyzes the precursor to bioorthogonal reaction by ultrasound induction;
the composition is used for in-situ synthesis of an ultrasonic mediated active medicament, and the precursor is 5-azido-1, 2, 3-trimethoxybenzene and 5-acetylene-2-methoxyaniline.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210294854.XA CN114939162B (en) | 2022-03-24 | 2022-03-24 | Multifunctional nano catalyst for ultrasonic-mediated bio-orthogonal reaction and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210294854.XA CN114939162B (en) | 2022-03-24 | 2022-03-24 | Multifunctional nano catalyst for ultrasonic-mediated bio-orthogonal reaction and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114939162A CN114939162A (en) | 2022-08-26 |
| CN114939162B true CN114939162B (en) | 2023-04-18 |
Family
ID=82905748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210294854.XA Active CN114939162B (en) | 2022-03-24 | 2022-03-24 | Multifunctional nano catalyst for ultrasonic-mediated bio-orthogonal reaction and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114939162B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111171080B (en) * | 2020-01-08 | 2021-11-12 | 南京师范大学 | High-efficiency low-toxicity anticancer compound synthesized by autocatalysis in cells and living bodies and synthesis method thereof |
| CN115551405A (en) * | 2020-05-06 | 2022-12-30 | 加利福尼亚大学董事会 | Bioorthogonal catalytic patch and method of use thereof |
| CN112656943B (en) * | 2020-12-30 | 2022-12-23 | 临沂大学 | Preparation method and application of copper monoatomic/gold cluster multifunctional diagnosis and treatment agent |
| CN113563293B (en) * | 2021-08-24 | 2022-12-30 | 苏州大学 | N-oxide based prodrug complex, preparation method and application thereof |
-
2022
- 2022-03-24 CN CN202210294854.XA patent/CN114939162B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114939162A (en) | 2022-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110819339B (en) | Cu-amino acid composite up-conversion nano material and preparation method thereof | |
| Wu et al. | MoO3-x nanosheets-based platform for single NIR laser induced efficient PDT/PTT of cancer | |
| Gao et al. | AuNRs@ MIL-101-based stimuli-responsive nanoplatform with supramolecular gates for image-guided chemo-photothermal therapy | |
| CN111358964A (en) | Magnetic octahedral platinum-doped gold nanoshell, and preparation method and application thereof | |
| CN112807430A (en) | Application of nano enzyme-based material | |
| Dong et al. | GQDs/hMSN nanoplatform: Singlet oxygen generation for photodynamic therapy | |
| Yang et al. | Tirapazamine-loaded UiO-66/Cu for ultrasound-mediated promotion of chemodynamic therapy cascade hypoxia-activated anticancer therapy | |
| Fan et al. | Mesoporous peroxidase nanozyme for synergistic chemodynamic therapy and chemotherapy | |
| CN111184861B (en) | Preparation method of tamoxifen-based metal-nano medicine, product and application thereof | |
| CN115518154B (en) | FeCuNC nano material, preparation and application thereof | |
| CN115945220B (en) | Ir metal-based biocatalyst and preparation method and application thereof | |
| CN112972423A (en) | Cascade reaction-based nano enzyme and chemotherapeutic drug co-loaded bionic nano drug carrier and preparation method and application thereof | |
| CN110354276B (en) | Prodrug and preparation method and application thereof | |
| CN109550050B (en) | Melanin-loaded molybdenum dioxide drug-loaded compound and preparation and application thereof | |
| CN114939162B (en) | Multifunctional nano catalyst for ultrasonic-mediated bio-orthogonal reaction and preparation method and application thereof | |
| CN114159588B (en) | Ternary alloy PtW-Mn-based nano probe, preparation method and application thereof | |
| CN114015064B (en) | Porphyrin MOF nanosheet with ultrasonic stimulus response, and preparation method and application thereof | |
| CN110917172B (en) | Molybdenum oxide nanosheet plugging hollow mesoporous silicon nanomaterial and preparation and application thereof | |
| CN114620756A (en) | Preparation method, product and application of gold-cerium oxide nano material | |
| CN114177200A (en) | HABT-C nano material and preparation and application thereof | |
| CN113244417A (en) | CaO2/MnFe2O4Nanocomposite material, preparation and application thereof | |
| CN113244394A (en) | Nanoparticle material with diagnosis and treatment functions and preparation method thereof | |
| Xu et al. | Cu2+-pyropheophorbide-a-cystine conjugate-mediated multifunctional mesoporous silica nanoparticles for photo-chemodynamic therapy/GSH depletion combined with immunotherapy cancer | |
| CN116196438B (en) | Preparation method of oxidation-responsive nano preparation | |
| CN114246946B (en) | Nanometer contrast agent for diagnosis and treatment integration and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |